Open Access

Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance

  • Authors:
    • Jingdong Wu
    • Yongfei Yang
    • Jiansheng Song
  • View Affiliations

  • Published online on: August 31, 2020     https://doi.org/10.3892/ol.2020.12043
  • Article Number: 182
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety‑eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their clinical data was retrospectively analyzed. The expression of SLC17A9 in HCC cancer tissues was detected by immunohistochemistry. Kaplan‑Meier curve, log‑rank test and Cox proportional hazard model analysis were used to analyze the tumor‑free survival rate and overall survival rate. SLC17A9 expression was associated with Edmondson grade (P=0.04) and distant metastasis (P=0.03). The tumor‑free survival (P=0.03) and overall survival (P=0.01) of SLC17A9‑high expression patients were significantly lower than those in SLC17A9‑low expression patients. Multivariate analysis revealed that SLC17A9 expression (HR, 0.77; 95% CI, 0.27‑2.47, P=0.02) was an independent risk factor for tumor‑free survival in patients with HCC, and the expression of SLC17A9 (HR, 1.81; 95% CI, 0.99‑3.77, P=0.04) was an independent risk factor for overall survival in patients with HCC. In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu J, Yang Y and Song J: Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance. Oncol Lett 20: 182, 2020
APA
Wu, J., Yang, Y., & Song, J. (2020). Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance. Oncology Letters, 20, 182. https://doi.org/10.3892/ol.2020.12043
MLA
Wu, J., Yang, Y., Song, J."Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance". Oncology Letters 20.5 (2020): 182.
Chicago
Wu, J., Yang, Y., Song, J."Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance". Oncology Letters 20, no. 5 (2020): 182. https://doi.org/10.3892/ol.2020.12043